Although increasing evidences demonstrate NSCLCs with EGFR activation may predict a poorer response to immunotherapy of PD-1/PD-L1inhibitors, whether immune surveillance influence the efficacy of EGFR-TKIs remains unclear.[30–33] Clarifying the relationship between PD-L1 expression and EGFR-TKI treatment may contribute to identify the NSCLC populations who would be most benefit from molecular-targeted therapy precisely. Here, EGFR is linked to non-small cell lung carcinoma.